Pay in 4 interest-free payments of $5.41 Learn more
Ships within 48 hours · Estimated delivery Oct 14 - Oct 19
A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer
Your physician will review your full medical history before prescribing
However, certain medical conditions, surgical procedures, or other factors could prevent you from seeking compensation
If you experience mood changes, know that your feelings are real and worth taking seriously
Merck began trials of the HMG-CoA reductase inhibitor lovastatin in 1980, and won a historic approval in 1987-- showing the medication produced robust reductions in LDL levels
US$ 21.33
US$ 25.90
US$ 25.91
US$ 23.61
US$ 23.99
US$ 26.60
